NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

MBX Biosciences, Inc. (MBX) Stock Analysis

MBX Biosciences, Inc. (MBX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MBX

$53.93

+$0.43 (+0.80%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MBX with… →

MBX Key Statistics

As of Oct 21, 2026
Trading
Open
$53.87
Previous Close
$53.50
Day's Range
53.44–56.20
52-Week Range
14.61–72.64
Volume
400.36K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.10
Valuation
Market Cap
$2.60B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.37
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$86.97M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.16M
1-Year Return
+252.25%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
518.65K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MBX closed at $53.93, +252.25% over 1 year.

MBX Biosciences, Inc. (MBX) has a market capitalization of $2.60B.

In fiscal 2025, MBX reported revenue of $0.00.

MBX Stock Return by Calendar Year

MBX Biosciences, Inc. (MBX) return since Sep 2024: what $10,000 became

1 year
$10,000 $35,225
+252.25%
Since Sep 2024
$10,000 $22,803
+128.03%

If you had invested $10,000 in MBX Biosciences, Inc. (MBX) at the close on September 13, 2024, the earliest close on record here, it would have been worth $22,803 at the close on October 21, 2026: +128.03% in total, +48.00% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+70.99%
2025+71.13%
2024 (partial year)−22.07%

As of October 21, 2026.

MBX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$86.97M—
2024$0.00−$61.92M—
2023$0.00−$32.56M—
2022$0.00−$26.14M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$98.06M−$86.97M—
2024$0.00—−$68.19M−$61.92M—
2023$0.00—−$35.31M−$32.56M—
2022$0.00—−$25.16M−$26.14M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

MBX Biosciences, Inc. (MBX) is capitalised at $2.60B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 63.

The 52-week range on file runs from $14.61 to $72.64. The most recent close on file for MBX is $53.93, dated October 21, 2026. That is +$0.43 (+0.80%) against the previous close. The latest close sits 269.13% above that 52-week low.

Financial Health

In fiscal 2025, MBX Biosciences, Inc. reported revenue of $0.00. The same year closed with a net loss of $86.97M. Trailing earnings per share are −2.37.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is +252.25%. The stored price history starts on September 13, 2024, and the total return since then is +128.03%. Beta against the wider market is reported at 0.1. Daily returns over the trailing 2 years annualize to a volatility of 113.09%.

Growth & Income

The record shows no dividend for MBX.

The record holds one complete calendar year, 2025, which returned +71.13%. So far in 2026 the total return is +70.99%.

Peer Comparison

MBX Biosciences, Inc. (MBX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MBX Biosciences, Inc. MBX $2.60B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. MBX Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About MBX Biosciences, Inc.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Visit website →